Navigation Links
Rigel Announces Presentations at Two Investor Conferences
Date:10/28/2009

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

    Oppenheimer 20th Annual Healthcare Conference
    Waldorf Astoria, New York City, NY
    November 3, 2:10 p.m. EST
    Speaker: Raul R. Rodriguez

    Credit Suisse 18th Annual Healthcare Conference
    Arizona Biltmore Hotel, Phoenix, AZ
    November 11, 2:00 p.m. MST
    Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Raul R. Rodriguez
    Phone: 650-624-1302
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com

SOURCE Rigel Pharmaceuticals, Inc.


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
6. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis today filled prescriptions ... Minnich,s Pharmacy in York to ... by Dr. Levine as a prescription to acquire naloxone ... "It,s important to remember that any Pennsylvanian can walk ...
(Date:12/5/2016)... Research and Markets has announced the ... Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & ... report to their offering. ... , , The western ... from USD 574.8 Million in 2016, growing at a CAGR of ...
(Date:12/5/2016)... CALEDONIA, Mich. , Dec. 5, 2016  Sharn ... a preferred anesthesia sales and distribution partner for Salter ... Dealer of the Year in recognition of outstanding sales ... of devices for respiratory and anesthesia care, including the ... company is also the master distributor of the Parker ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins ... growing brains of young athletes. Over the course of three years, researchers will study ... mouth guards. The mouth guards, equipped with special sensors, will track the location and ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... Isles Beach, Fla (PRWEB) , ... December 05, ... ... E. Herman as Keynote speaker for the 21st Annual International Congress on Hematologic ... making the announcement, PER® president, Phil Talamo said, “We are honored to have ...
(Date:12/5/2016)... Missouri (PRWEB) , ... December 05, 2016 , ... ... ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has always ... treatment accessible to as many people as possible. In that spirit, Castlewood ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
Breaking Medicine News(10 mins):